1. Patients launch a $1.27 million crowdfunding campaign for ME/CFS gut microbiome study.
    Check out the website, Facebook and Twitter. Join in donate and spread the word!
The Fable known as The PACE Trial
Graham, Janelle and Bob, have once again excelled themselves with their latest take on the 'poisoned apple' that was the PACE Trial...
Discuss the article on the Forums.

Status of Rituximab-ME/CFS Studies

Discussion in 'Rituximab: News and Research' started by Persimmon, Feb 15, 2012.

  1. lansbergen

    lansbergen Senior Member

    Messages:
    911
    Likes:
    367
    .
    My guess: If new Tcells are spared from this they might work properly but it will take time to get enouigh healthy Tcells.
  2. liquid sky

    liquid sky Senior Member

    Messages:
    344
    Likes:
    151
    "Ocrelizumab has previously been investigated as a treatment for rheumatoid arthritis but studies were discontinued because of a high incidence of opportunistic infections in participants. Opportunistic infections are infections that do not normally occur in a healthy person but may occur when the immune system is compromised."

    This new B cell depletion drug, Ocrelizumab, has not been safer than Rituxan. Rituxan has been approved for years in RA with a good safety profile. http://www.medpagetoday.com/MeetingCoverage/ACR/35895

See more popular forum discussions.

Share This Page